TECLens, Inc. raised $9.3 million in a Series A funding round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital to advance its non-invasive refractive technology.

Feb 11, 2025•10 months ago

Amount Raised

$9.3 Million

Round Type

series a

StamfordHealth Care

Investors

Sunmed CapitalRimonci CapitalYonjin CapitalJohnson & Johnson Innovation – Jjdc Inc.

Description

TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today it raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. The funding will support the clinical development of the company’s non-incisional refractive correction procedure.

Company Information

Company

TECLens

Location

9 RIVERBEND DR S

Stamford, Connecticut, United States

About

TECLens is a clinical-stage ophthalmic medical device company, pioneering non-invasive personalized corneal cross-linking technology (qCXL™) for vision correction. Our innovative CXLens® system uses patterned ultraviolet (UV) light to gently reshape the cornea with continuous biomechanical control. qCXL is designed to be a comfortable, safe, and effective alternative to traditional refractive surgeries. TECLens’ breakthrough technology aims to set a new standard in precision, accessibility, and patient experience—redefining vision correction with innovation that improves quality of life.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns